Leadership
A Panel Discussion among Eight Endocrinologists
Price $2500
Deliverable: Transcript with key findings.
Study Description and Objectives:
Panel Intelligence engaged a set of eight endocrinologists to discuss data presented at the American Diabetes Association (ADA) 68th Scientific Sessions about GLP-1 analogs including Novo Nordisk’s LEAD trials about liraglutide (NN221), Amylin Pharmaceutical and Eli Lilly’s Byetta® (exenatide) and exenatide LAR, and Roche Pharmaceutical’s study of taspoglutide (R1583) in an online panel discussion. Secondary objectives of this study included the following:
§ Understand the current clinical experience with Byetta for type 2 diabetics.
§ Analyze the results of Novo Nordisk’s comparative liraglutide studies with rosiglitazone, glimepiride, and insulin glargine.
§ Analyze the liraglutide vs. Byetta head-to-head LEAD 6 study.
· Assess the likelihood for FDA approval of liraglutide.
· Assess the potential impact of FDA approval for liraglutide on the use of Byetta.
§ Analyze the efficacy and safety results for the Byetta vs. exenatide LAR study.
§ Analyze the efficacy and safety results for Roche’s taspoglutide dosing study.
§ Discuss the possible impact FDA approval of liraglutide, exenatide LAR and taspoglutide might have on the use of Byetta and other current diabetic therapies.
Companies and Products Mentioned in This Report:
|
Company |
Ticker Symbol |
Products |
|
Amylin |
AMLN |
Byetta® (exenatide), exenatide LAR |
|
Eli Lilly |
LLY |
Byetta® (exenatide), exenatide LAR |
|
Alkermes |
ALKS |
exenatide LAR |
|
GlaxoSmithKline |
GSK |
Avandia® (rosiglitazone) |
|
Novo Nordisk |
NVO |
liraglutide |
|
Sanofi Aventis |
SNY |
Amaryl® (glimepiride), Lantus®, (insulin glargine) |
Inclusion Criteria and Panelist Details:
|
Inclusion Criteria |
§ US-based physicians § Training and board-certified in endocrinology § 2 to 30 years of experience post-training § From community hospitals or private practices § Treat a significant number type 2 diabetic patients per month § Spends at least 75% of their time in clinical practice § Can not have affiliations with Amylin Pharmaceuticals, Eli Lilly, Novo Nordisk, or Roche Pharmaceuticals, or have participated in the clinical trials being discussed |
|
Discussion Dates |
June 17, 2008 through June 26, 2008 |
To purchase this report or request additional information, contact:
Print Abstract
For additional information on this study or to purchase, please call:
|
Discussion
Endocrinology |